Primary and secondary outcomes of the whole cohort
TNBC
Patients were enrolled into one of the following arms based on their TNBC subtypes and genomic features: (A) pyrotinib with capecitabine, (B) androgen receptor inhibitor backbone therapy, (C) anti-PD-1 with nab-paclitaxel, (D) PARP inhibitor backbone therapy, (E) anti-VEGF/VEGFR backbone therapy, (F) VEGFR inhibitor backbone therapy, and (G) mTOR inhibitor with nab-paclitaxel (Fig. 